Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patients

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1441-1446

  Maruyama, Katsuhiko ^a   Tsuchisaka, Asako ^a   Sakamoto, Jumpei ^a   Shirato, Shiroaki ^b   Goto, Hiroshi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Yotsuya Shirato Eye Clinic   (Japan)

Author keywords

Deepening; Eyelid; Prostaglandins; Side effect; Tafluprost

Indexed keywords

TAFLUPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEPENING OF UPPER EYELID SULCUS; DISEASE ASSOCIATION; DISEASE SEVERITY; EYE REFRACTION; EYELID DISEASE; FEMALE; GENDER; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; JAPANESE; MALE; OPEN ANGLE GLAUCOMA; OPEN STUDY; PRESCRIPTION; PROSPECTIVE STUDY;

EID: 84880274086     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S47783     Document Type: Article

References (21)

1. Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6(1):45-52.
2. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81(8):574-577.
3. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008;24(4):302-307.
4. Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D. [Orbital fat atrophy in glaucoma patients treated with topical bimatoprost-can bimatoprost cause enophthalmos?] Klin Monbl Augenheilkd. 2008;225(5): 443-445. German.
5. Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther. 2009;25(5): 471-472.
6. Jayaprakasam A, Ghazi-Nouri S. Periorbital fat atrophy-an unfamiliar side effect of prostaglandin analogues. Orbit. 2010;29(6):357-359.
7. Nakakura S, Tabuchi H, Kiuchi Y. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost. Optom Vis Sci. 2011;88(9):1140-1144.
8. Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol. 2011;55(6):600-604.
9. Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the Upper Eyelid Sulcus Caused by 5 Types of Prostaglandin Analogs. J Glaucoma. Epub August 29, 2012.
10. Suh MH, Park KH, Kim DM. Effect of travoprost on intraocular pres- sure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol. 2009;53(1):18-23.
11. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid supe- rior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53(2):176-179.
12. Maruyama K, Shirato S, Tsuchisaka A. Incidence of deepening of the upper eyelid sulcus after topical use of travoprost ophthalmic solution in Japanese. J Glaucoma. Epub August 23, 2012.
13. Ung T, Currie ZI. Periocular changes following long-term administra- tion of latanoprost 0.005%. Ophthal Plast Reconstr Surg. 2012;28(2): e42-e44.
14. Uusitalo H, Pillunat LE, Ropo A; Phase III Study Investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88(1):12-19.
15. Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26(1):97-104.
16. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55(1):22-27.
17. Serrero G, Lepak NM. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary cul- ture of adipocyte precursors in defined medium. Biochem Biophys Res Commun. 1997;233(1):200-202.
18. Liu L, Clipstone NA. Prostaglandin F2alpha inhibits adipocyte dif- ferentiation via a G alpha q-calcium-calcineurin-dependent signaling pathway. J Cell Biochem. 2007;100(1):161-173.
19. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19(6):501-515.
20. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP recep- tor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78(4): 767-776.
21. Choi HY, Lee JE, Lee JW, Park HJ, Lee JE, Jung JH. In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes. J Ocul Pharmacol Ther. 2012;28(2):146-152.